Sphingolipid metabolism and drug resistance in ovarian cancer

Abstract

Despite progress in understanding molecular aberrations that contribute to the development and progression of ovarian cancer, virtually all patients succumb to drug resistant disease at relapse. Emerging data implicate bioactive sphingolipids and regulation of sphingolipid metabolism as components of response to chemotherapy or development of resistance. Increases in cytosolic ceramide induce apoptosis in response to therapy with multiple classes of chemotherapeutic agents. Aberrations in sphingolipid metabolism that accelerate the catabolism of ceramide or that prevent the production and accumulation of ceramide contribute to resistance to standard of care platinum- and taxane-based agents. The aim of this review is to highlight current literature and research investigating the influence of the sphingolipids and enzymes that comprise the sphingosine-1-phosphate pathway on the progression of ovarian cancer. The focus of the review is on the utility of sphingolipid-centric therapeutics as a mechanism to circumvent drug resistance in this tumor type.

Keywords

Ovarian cancer / drug-resistance / ceramide / sphingosine-1-phosphate / sphingolipid metabolism

References

[1] Romero I.Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.Endocrinology2012;153:1593-602 PMCID:PMC3320264

[2] Jayson GC,Kitchener HC.Ovarian cancer.Lancet2014;384:1376-88

[3] Eckstein N.Platinum resistance in breast and ovarian cancer cell lines.J Exp Clin Cancer Res2011;30:91 PMCID:PMC3197542

[4] Hannun YA.Sphingolipids and their metabolism in physiology and disease.Nat Rev Mol Cell Biol2018;19:175-91

[5] Patwardhan GA.Sphingolipids and expression regulation of genes in cancer.Prog Lipid Res2011;50:104-14 PMCID:PMC3012148

[6] Babahosseini H,Schmelz EM.Roles of bioactive sphingolipid metabolites in ovarian cancer cell biomechanics.Conf Proc IEEE Eng Med Biol Soc2012;2012:2436-9

[7] Ogretmen B.Sphingolipid metabolism in cancer signalling and therapy.Nat Rev Cancer2018;18:33-50 PMCID:PMC5818153

[8] Ogretmen B.Biologically active sphingolipids in cancer pathogenesis and treatment.Nat Rev Cancer2004;4:604-16

[9] Ponnusamy S,Senkal CE,Sentelle D,Salas A.Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.Future Oncol2010;6:1603-24 PMCID:PMC3071292

[10] Pyne NJ,Lim KG,Edwards J.Sphingosine 1-phosphate signalling in cancer.Biochem Soc Trans2012;40:94-100

[11] Pyne NJ.Sphingosine 1-phosphate and cancer.Nat Rev Cancer2010;10:489-503

[12] Hannun YA.Principles of bioactive lipid signalling: lessons from sphingolipids.Nat Rev Mol Cell Biol2008;9:139-50

[13] Kunkel GT,Milstien S.Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.Nat Rev Drug Discov2013;12:688-702 PMCID:PMC3908769

[14] Sentelle RD,Jiang W,Gencer S,Ramshesh VK,Lemasters JJ,Bielawski J.Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy.Nat Chem Biol2012;8:831-8 PMCID:PMC3689583

[15] Morad SA.Ceramide-orchestrated signalling in cancer cells.Nat Rev Cancer2013;13:51-65

[16] Spiegel S.Sphingosine-1-phosphate: an enigmatic signalling lipid.Nat Rev Mol Cell Biol2003;4:397-407

[17] Mahajan-Thakur S,Marx S,Rauch BH.Sphingosine 1-phosphate (S1P) signaling in glioblastoma multiforme-a systematic review.Int J Mol Sci2017;18:E2448 PMCID:PMC5713415

[18] Gault CR,Hannun YA.An overview of sphingolipid metabolism: from synthesis to breakdown.Adv Exp Med Biol2010;688:1-23 PMCID:PMC3069696

[19] Takabe K,Milstien S."Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.Pharmacol Rev2008;60:181-95 PMCID:PMC2695666

[20] Liu YY,Li YT.Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.Adv Cancer Res2013;117:59-89 PMCID:PMC4051614

[21] Olivera A,Proia RL.Shaping the landscape: metabolic regulation of S1P gradients.Biochim Biophys Acta2013;1831:193-202 PMCID:PMC3484219

[22] Garcia-Barros M,Truman JP,Hannun YA.Sphingolipids in colon cancer.Biochim Biophys Acta2014;1841:773-82 PMCID:PMC3962523

[23] Park KS,Lee HY,Lee SY,Ryu SH.S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells.Biochem Biophys Res Commun2007;356:239-44

[24] Wang D,Caperell-Grant A,Mok SC,Bigsby RM.S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells.Mol Cancer Ther2008;7:1993-2002 PMCID:PMC2649755

[25] Smicun Y,Wang FQ,Fishman DA.S1P regulation of ovarian carcinoma invasiveness.Gynecol Oncol2006;103:952-9

[26] Smicun Y,Devine K.S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells.Gynecol Oncol2007;107:298-309

[27] Dobbin ZC,Steg AD,Shah MM,Conner MG,Chen D.Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.Oncotarget2014;5:8750-64 PMCID:PMC4226719

[28] Lee AJ,Sander J,Endesfelder D,Jones NP,Nicke B,Obeid LM,Szallasi Z,Rowan AJ,Hanby AM,Tooze SA.CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.J Pathol2012;226:482-94

[29] Lee JW,Yoon G,Cho YJ,Song SY,Lee YY,Choi CH,Bae DS.Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.Int J Cancer2015;137:221-9

[30] Devalapally H,Seiden MV.Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.Clin Cancer Res2008;14:3193-203

[31] Prinetti A,Appierto V,Valsecchi M,Prioni S,Cavadini E,Sonnino S.Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells.J Biol Chem2003;278:5574-83

[32] Swanton C,Pardo O,Kelly G,Elustondo F,Temple J,Brenton JD,Nicke B.Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.Cancer Cell2007;11:498-512

[33] Kolesnick R,Fuks Z.A CERTain role for ceramide in taxane-induced cell death.Cancer Cell2007;11:473-5

[34] Liu YY,Bhinge K,Gu X.Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.Cancer Res2011;71:2276-85 PMCID:PMC3059346

[35] Suh DH,Kim B.Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication.Biochem Pharmacol2014;92:43-54

[36] Gouaze-Andersson V.Glycosphingolipids and drug resistance.Biochim Biophys Acta2006;1758:2096-103

[37] Best C,Szulak K,Brum G,Still E,Ji F,Wanebo H.Paclitaxel disrupts polarized entry of membrane-permeable C6 ceramide into ovarian cancer cells resulting in synchronous induction of cell death.Oncol Lett2013;5:1854-8 PMCID:PMC3701061

[38] Prinetti A,D'Ascenzo S,Bettiga A,Sonnino S,Dolo V.Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.Biochem J2006;395:311-8 PMCID:PMC1422777

[39] El Kaffas A,Hashim A,Giles A.Role of acid sphingomyelinase and ceramide in mechano-acoustic enhancement of tumor radiation responses.J Natl Cancer Inst2018;

[40] Oskouian B.Cancer treatment strategies targeting sphingolipid metabolism.Adv Exp Med Biol2010;688:185-205 PMCID:PMC3076281

[41] Dai L,Di W.Sphingosine 1-phosphate: a potential molecular target for ovarian cancer therapy?.Cancer Invest2014;32:71-80

[42] Dai L,Xie L,Qiu L.Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis.Oncotarget2017;8:74947-61 PMCID:PMC5650392

[43] Schwartz BM,Morrison BH,Baudhuin LM,Mok SC.Lysophospholipids increase interleukin-8 expression in ovarian cancer cells.Gynecol Oncol2001;81:291-300

[44] Hatoum D,Lin Y,McGowan EM.Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.Oncotarget2017;8:36898-929 PMCID:PMC5482707

[45] Maceyka M,Hait NC,Liu H,Collier C,Satin LS,Milstien S.SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism.J Biol Chem2005;280:37118-29

[46] Siow D.The compartmentalization and translocation of the sphingosine kinases: mechanisms and functions in cell signaling and sphingolipid metabolism.Crit Rev Biochem Mol Biol2011;46:365-75 PMCID:PMC3183286

[47] Gao Y,Chen K,Zhao DL.Sphingosine kinase 1 as an anticancer therapeutic target.Drug Des Devel Ther2015;9:3239-45 PMCID:PMC4484649

[48] Datta A,Huang B,Tan SS,Lee SC,Lim YC,Lam Y,Yap CT.SPHK1 regulates proliferation and survival responses in triple-negative breast cancer.Oncotarget2014;5:5920-33 PMCID:PMC4171602

[49] Pchejetski D,Stebbing J.Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.Nat Rev Urol2011;8:569-678

[50] Hait NC,Maceyka M,Harikumar KB,Luo C,Kordula T,Spiegel S.Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.Science2009;325:1254-7 PMCID:PMC2850596

[51] Taha TA,Kozhaya L,Johnson KR,Dbaibo GS,Obeid LM.Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53.J Biol Chem2004;279:20546-54

[52] Kim HS,Ryu JY,Choi JJ,Kim TJ,Song SY,Bae DS.Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.Oncotarget2015;6:26746-56

[53] Truman JP,Obeid LM.Evolving concepts in cancer therapy through targeting sphingolipid metabolism.Biochim Biophys Acta2014;1841:1174-88 PMCID:PMC4221100

[54] Yang YL,Cheng L,Lu CC,Bi ZG.Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells.Cancer Sci2012;103:1538-45

[55] Beach JA,Cheon DJ,Agadjanian H,Karlan BY.Sphingosine kinase 1 is required for TGF-beta mediated fibroblastto- myofibroblast differentiation in ovarian cancer.Oncotarget2016;7:4167-82 PMCID:PMC4826197

[56] Neubauer HA.Roles, regulation and inhibitors of sphingosine kinase 2.FEBS J2013;280:5317-36

[57] Liu H,Goparaju SK,Nava VE,Payne SG,Ishii I,Milstien S.Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis.J Biol Chem2003;278:40330-6

[58] Gao P.Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration.Mol Cancer Res2011;9:1509-19 PMCID:PMC3219805

[59] Sankala HM,Paugh SW,Lepine S,Dent P,Spiegel S.Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin.Cancer Res2007;67:10466-74

[60] Schnitzer SE,Zhou J.Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells.Mol Cancer Res2009;7:393-401

[61] Hait NC,Yamada A,Aoyagi T,Dumur CI,Gallagher EJ,Milstien S,Spiegel S.The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERalpha expression and enhances hormonal therapy for breast cancer.Oncogenesis2015;4:e156 PMCID:PMC4753524

[62] Kartal Yandim M,Baran Y.Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer.Cancer Chemother Pharmacol2013;71:13-20

[63] Hanada K.Intracellular trafficking of ceramide by ceramide transfer protein.Proc Jpn Acad Ser B Phys Biol Sci2010;86:426-37 PMCID:PMC3417804

[64] Yamaji T,Tomishige N.Two sphingolipid transfer proteins, CERT and FAPP2: their roles in sphingolipid metabolism.IUBMB Life2008;60:511-8

[65] Lin HY,Vang O,Lin S,Chiang HL,Tang HY,Whang-Peng J,Liu LF.Mechanisms of ceramide-induced COX-2-dependent apoptosis in human ovarian cancer OVCAR-3 cells partially overlapped with resveratrol.J Cell Biochem2013;114:1940-54

[66] Rajanayake KK,Isailovic D.The comparison of glycosphingolipids isolated from an epithelial ovarian cancer cell line and a nontumorigenic epithelial ovarian cell line using MALDI-MS and MALDI-MS/MS.Carbohydr Res2016;431:6-14

[67] Roh JL,Park JY.Inhibition of glucosylceramide synthase sensitizes head and neck cancer to cisplatin.Mol Cancer Ther2015;14:1907-15

[68] Gouaze V,Prickett CS,Giuliano AE.Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.Cancer Res2005;65:3861-7

[69] Liu YY,Patwardhan GA,Zhao Y,Mehendale H,Li YT.Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.Mol Cancer2010;9:145 PMCID:PMC2903501

[70] Liu YY,Giuliano AE.Ceramide glycosylation potentiates cellular multidrug resistance.FASEB J2001;15:719-30

[71] Morad SA,Levin JC,Karimi R,Kester M,Cabot MC.Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53.Biochem Pharmacol2013;85:1057-65 PMCID:PMC3604153

[72] Juul N,Eklund AC,Burrell RA,Valero V,Esteva FJ,Desmedt C,Sotiriou C,Swanton C.Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.Lancet Oncol2010;11:358-65

[73] Lucci A,Han TY,Liu YY,Cabot MC.Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells.Int J Oncol1999;15:535-40

[74] Patwardhan GA,Liu DX,Zhao Y,Jazwinski SM.Ceramide modulates pre-mRNA splicing to restore the expression of wild-type tumor suppressor p53 in deletion-mutant cancer cells.Biochim Biophys Acta2014;1841:1571-80 PMCID:PMC4188706

[75] Atilla-Gokcumen GE,Sasse S.Inhibition of glycosphingolipid biosynthesis induces cytokinesis failure.J Am Chem Soc2011;133:10010-3 PMCID:PMC3131740

[76] Liu J,Foroozesh M.A review of ceramide analogs as potential anticancer agents.Future Med Chem2013;5:1405-21 PMCID:PMC4216473

[77] van Vlerken LE,Seiden MV.Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.Cancer Res2007;67:4843-50

[78] Overbye A,Markus F,Iversen TG,Sonstevold T,Flatmark K,Skotland T.Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.Oncotarget2017;8:76921-34 PMCID:PMC5652752

[79] Lucci A,Liu YY,Cabot MC.Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics.Int J Oncol1999;15:541-6

[80] Qiu L,Sun Y,Scheffler E,Wanebo H,Chu W.Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells.Oncol Rep2006;16:907-13

[81] Zhu QY,Ji C,Yang YL,Jin YH,Gu XJ,Hu G.C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo.Cell Death Dis2011;2:e117 PMCID:PMC3077291

[82] Zhang X,Toyoshima M,Usui T,Egiz M,Fox T,Kester M.Ceramide nanoliposomes as a MLKL-dependent, necroptosis-inducing, chemotherapeutic reagent in ovarian cancer.Mol Cancer Ther2018;17:50-9

[83] Devalapally H,Seiden MV.Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer.Int J Cancer2007;121:1830-8

[84] Stover TC,Lowe TL.Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug.Biomaterials2008;29:359-69

[85] Stover TC,Robertson GP.Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.Clin Cancer Res2005;11:3465-74

[86] Tran MA,Kester M.Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.Clin Cancer Res2008;14:3571-81

[87] Tagaram HR,Barth BM,Avella D,Jiang Y,Kester M.Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma.Gut2011;60:695-701

[88] Liu X,Yang J,Aliaga C,Tan SF,Shanmugavelandy SS,Loughran K,Yuen J,Baab KT,Broeg K,Liao J,Kester M.Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.Blood2010;116:4192-201 PMCID:PMC2993625

[89] Jiang Y,Kaiser JM,Fritz JL,Tagaram HR,Cabot MC,Tran MA,Barth BM.Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.Cancer Biol Ther2011;12:574-85 PMCID:PMC3218384

[90] Adiseshaiah PP,McLeland CB,Potter TM,Skoczen SL,Kester M,McNeil SE.Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models.Cancer Lett2013;337:254-65 PMCID:PMC3722309

[91] Ryland LK,Shanmugavelandy SS,Aliaga C,Baab KT,Khan O,Jarbadan NR,Wang HG,Loughran TPJr,Kester M.C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia.PLoS One2013;8:e84648 PMCID:PMC3868606

[92] Kester M,Fox TE,Davidson JA.Preclinical development of a C6-ceramide nanoLiposome, a novel sphingolipid therapeutic.Biol Chem2015;396:737-47

[93] Wang T,Yang S,Zhang N.Ceramide lipid-based nanosuspension for enhanced delivery of docetaxel with synergistic antitumor efficiency.Drug Deliv2017;24:800-10

[94] Kitatani K,Sriraman SK,Ishibashi M,Nagase S,Ogiso H,Hannun YA,Yaegashi N.Ceramide limits phosphatidylinositol-3-kinase C2beta-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.Oncogene2016;35:2801-12 PMCID:PMC4791218

[95] O'Brien N,Williams DG,Moreno K,Gentile A,Shestowsky W,Matteo R,Grotjahn D,Hansen G,Sabbadini R.Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies.J Lipid Res2009;50:2245-57 PMCID:PMC2759830

[96] Visentin B,Sibbald BJ,Moreno KM,Garland WA,Yu S,Kundra V,Sabbadini RA.Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages.Cancer Cell2006;9:225-38

[97] Ader I,Bouquerel P,Andrieu G,Richard S,Malavaud B.Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer.Oncotarget2015;6:13803-21 PMCID:PMC4537051

[98] Pal SK,Reeves JA,Hazel SE,Wojciak J,Bhatt RS.A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.Cancer2017;123:576-82

[99] Zhang L,Bullock AJ,Shah H,Moreno K,Deutschman D,Atkins MB,Signoretti S,Sabbadini RA.Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer.Clin Cancer Res2015;21:1925-34 PMCID:PMC4419371

[100] David OJ,Schmouder RL.Clinical pharmacokinetics of fingolimod.Clin Pharmacokinet2012;51:15-28

[101] Cohen JA,Comi G,Khatri BO,Pelletier J,Gallo P,Tiel-Wilck K,Jin J,Wu S,Kappos L.Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.N Engl J Med2010;362:402-15

[102] Kappos L,O'Connor P,Hohlfeld R,Selmaj K,Leyk M,Burtin P.A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N Engl J Med2010;362:387-401

[103] Comi G,Montalban X,Radue EW,Pohlmann H,Kappos L.Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.Mult Scler2010;16:197-207

[104] Patmanathan SN,Murray PG.The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.J Cell Mol Med2015;19:2329-40 PMCID:PMC4594675

[105] White C,Cooper C,Pchejetski D.The emerging role of FTY720 (Fingolimod) in cancer treatment.Oncotarget2016;7:23106-27 PMCID:PMC5029614

[106] Zhang N,Wadham C,Warren A,Xia P.FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy.Autophagy2010;6:1157-67

[107] Lim KG,Li Z,Bittman R,Pyne NJ.FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells.J Biol Chem2011;286:18633-40 PMCID:PMC3099679

[108] Tonelli F,Loveridge C,Pitson SM,Bittman R,Pyne NJ.FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.Cell Signal2010;22:1536-42 PMCID:PMC2947314

[109] Pitman MR,Lopez AF.Molecular targets of FTY720 (fingolimod).Curr Mol Med2012;12:1207-19

[110] White C,Cooper C,Pchejetski D.The emerging role of FTY720 (Fingolimod) in cancer treatment.Oncotarget2016;7:23106-27 PMCID:PMC5029614

[111] Hisano Y,Kawahara A,Nishi T.The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.J Biol Chem2011;286:1758-66 PMCID:PMC3023470

[112] Honig SM,Mao X,Gunn MD,Bromberg JS.FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes.J Clin Invest2003;111:627-37 PMCID:PMC151892

[113] Ishitsuka A,Mizutani Y,Kanoh H,Seishima M.FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression.Int J Mol Med2014;34:1169-74

[114] Li MH,Ferrer F.FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway.Pediatr Blood Cancer2013;60:1418-23 PMCID:PMC3751174

[115] Marvaso G,Amodio N,Agosti V,Scotti V,Bianco R,Caraglia M,Tagliaferri P.Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.Cancer Biol Ther2014;15:797-805 PMCID:PMC4049795

[116] Pchejetski D,Brizuela L,Doumerc N,Salunkhe V,Malavaud B,Cuvillier O.FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.Cancer Res2010;70:8651-61

[117] A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma.ClinicalTrials.gov Identifier: NCT02490930

[118] Dickson MA,Merrill AHJr,Cane LM.A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors.Clin Cancer Res2011;17:2484-92 PMCID:PMC3078945

[119] Coward J,Musi E,Haimovitz-Friedman A,Wang E,Schwartz GK.Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway.Autophagy2009;5:184-93

[120] Pitson SM.Regulation of sphingosine kinase and sphingolipid signaling.Trends Biochem Sci2011;36:97-107

[121] Neubauer HA,Zebol JR,Peterson AL,Chan H,Pitman MR,Bonder CS,Gliddon BL.An oncogenic role for sphingosine kinase 2.Oncotarget2016;7:64886-99 PMCID:PMC5323123

[122] White MD,Antoon JW.Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.Anticancer Res2013;33:3573-9

[123] Venkata JK,Stuart R,Cai H,Song JH,Matson T,Wan Z,Smith C.Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.Blood2014;124:1915-25 PMCID:PMC4168346

[124] Guan S,Yan T.Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.Biochem Biophys Res Commun2016;476:230-6

[125] Antoon JW,Meacham WD,Muir SE,Rhodes LV,Wiese TE,Burow ME.Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.Endocrinology2010;151:5124-35 PMCID:PMC2954724

[126] Schrecengost RS,Schiewer MJ,Smith CD.Downregulation of critical oncogenes by the selective SK2 inhibitor ABC294640 hinders prostate cancer progression.Mol Cancer Res2015;13:1591-601 PMCID:PMC4685021

[127] Lewis CS,Smith CD.Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.Oncotarget2016;7:60181-92 PMCID:PMC5312377

[128] Antoon JW,Bratton MR,Rhodes LV,Wiese TE,Beckman BS.Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer.J Mol Endocrinol2011;46:205-16 PMCID:PMC4007162

[129] Britten CD,Chin SH,Ogretmen B,Brisendine A,Cusack SL,Zhuang Y,Thomas MB.A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors.Clin Cancer Res2017;23:4642-50

[130] Osborne CK.Tamoxifen in the treatment of breast cancer.N Engl J Med1998;339:1609-18

[131] Morad SA.Tamoxifen regulation of sphingolipid metabolism--therapeutic implications.Biochim Biophys Acta2015;1851:1134-45 PMCID:PMC4516673

[132] Morad SA,Tan SF,Feith DJ.Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.Biochim Biophys Acta2013;1831:1657-64

[133] de Vincenzo R,Benedetti Panici P,Ercoli A,Pernisco S,Mancuso S.Chemosensitizing effect of tamoxifen and ICI 182,780 on parental and adriamycin-resistant MCF-7 human breast cancer cells.Ann N Y Acad Sci1996;784:517-20

[134] Ercoli A,De Vincenzo R,Petrucci F,Isola G,Caroli S.Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism.Cancer Lett1996;108:7-14

[135] Markman M.Second-line treatment of ovarian cancer.Oncologist2000;5:26-35

[136] Morad SA,Shanmugavelandy SS,Fabrias G,Cabot MC.Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.Mol Cancer Ther2012;11:2352-61 PMCID:PMC3495995

[137] Zhang N,Qi Y,Xia P.Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy.Int J Oncol2013;42:2053-9

[138] Illuzzi G,Aureli M,Frera G,Valsecchi M,Bruni P,Prinetti A.Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells.J Biol Chem2010;285:18594-602 PMCID:PMC2881785

[139] Casper ES,Sugarman A,Brennan MF.Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.J Clin Oncol1997;15:2111-7

[140] Schwartz GK,Saltz L,Spiess T,Woodworth J,Zervos P,Kelsen DP.A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.Clin Cancer Res1997;3:537-43